Annals of surgical oncology · 2026
Decision-Making and Decision Satisfaction Following Cytoreductive Surgery and HIPEC for GI Malignancies: A Qualitative Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bleicher Josh, Jiang Stephanie, Aksenchuk Sophia, McCart Andrea, Bischof Danielle, Covelli Andrea, Govindarajan Anand
Аннотация
BACKGROUND AND PURPOSE: For patients with aggressive gastrointestinal malignancies, cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) offers a chance for prolonged survival but comes with risks of morbidity, decreased quality of life, and-rarely-death. Decision-making for patients considering CRS/HIPEC is complex and understudied. This study explored how patients approached the decision to pursue CRS/HIPEC and how they perceived their decisions postoperatively.
METHODS: We performed a qualitative study with patients who underwent CRS/HIPEC between May 2023 and March 2024. Patients were interviewed using a semi-structured interview guide focused on understanding the decision-making process around CRS/HIPEC and assessing whether patients experienced decision regret after surgery. Transcripts were analyzed inductively using the constant comparative method.
RESULTS: In total, 14 of 18 patients completed interviews at a median of 16.9 months after CRS/HIPEC (median age 57 years; 50% women). We identified four key themes, which focused on patient sources of information about CRS/HIPEC, preoperative conversations about CRS/HIPEC, the decision-making-process, and decision satisfaction versus decision regret. Most patients felt they had little agency in the decision to pursue CRS/HIPEC but were trusting of their providers' recommendations. Decision regret was uncommon and most associated with recurrent disease when present. Patients placed high value on their disease-free interval and time away from chemotherapy.
DISCUSSION: This study offers an improved understanding of the decision-making process for patients pursuing CRS/HIPEC. Surgeons can use these data to improve preoperative counselling. Future quality-of-life studies should include questions to determine the value of chemotherapy-free intervals.
METHODS: We performed a qualitative study with patients who underwent CRS/HIPEC between May 2023 and March 2024. Patients were interviewed using a semi-structured interview guide focused on understanding the decision-making process around CRS/HIPEC and assessing whether patients experienced decision regret after surgery. Transcripts were analyzed inductively using the constant comparative method.
RESULTS: In total, 14 of 18 patients completed interviews at a median of 16.9 months after CRS/HIPEC (median age 57 years; 50% women). We identified four key themes, which focused on patient sources of information about CRS/HIPEC, preoperative conversations about CRS/HIPEC, the decision-making-process, and decision satisfaction versus decision regret. Most patients felt they had little agency in the decision to pursue CRS/HIPEC but were trusting of their providers' recommendations. Decision regret was uncommon and most associated with recurrent disease when present. Patients placed high value on their disease-free interval and time away from chemotherapy.
DISCUSSION: This study offers an improved understanding of the decision-making process for patients pursuing CRS/HIPEC. Surgeons can use these data to improve preoperative counselling. Future quality-of-life studies should include questions to determine the value of chemotherapy-free intervals.